[HTML][HTML] Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in …
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
LE Wright, AA Harhash, WM Kozlow, DL Waning… - Oncotarget, 2017 - europepmc.org
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
[PDF][PDF] Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in …
LE Wright, AA Harhash, WM Kozlow, DL Waning… - pdfs.semanticscholar.org
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
[引用][C] Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in …
LE Wright, AA Harhash, WM Kozlow, DL Waning… - Oncotarget, 2016 - cir.nii.ac.jp
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative
breast cancer in bone and exacerbates muscle weakness in vivo | CiNii Research CiNii 国立 …
breast cancer in bone and exacerbates muscle weakness in vivo | CiNii Research CiNii 国立 …
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
LE Wright, AA Harhash, WM Kozlow… - …, 2017 - pubmed.ncbi.nlm.nih.gov
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
LE Wright, AA Harhash, WM Kozlow… - …, 2017 - mdanderson.elsevierpure.com
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
[HTML][HTML] Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in …
LE Wright, AA Harhash, WM Kozlow, DL Waning… - Oncotarget, 2016 - oncotarget.com
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative
breast cancer in bone and exacerbates muscle weakness in vivo | Oncotarget Online ISSN …
breast cancer in bone and exacerbates muscle weakness in vivo | Oncotarget Online ISSN …
[PDF][PDF] Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in …
LE Wright, AA Harhash, WM Kozlow, DL Waning… - researchgate.net
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
LE Wright, AA Harhash, WM Kozlow, DL Waning… - Oncotarget, 2017 - pure.psu.edu
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone …
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
LE Wright, AA Harhash, WM Kozlow, DL Waning… - Oncotarget, 2016 - oncotarget.com
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative
breast cancer in bone and exacerbates muscle weakness in vivo | Oncotarget Online ISSN …
breast cancer in bone and exacerbates muscle weakness in vivo | Oncotarget Online ISSN …